BioMarin Pharmaceutical | BMRN - Operating Profit


BioMarin Pharmaceutical reported $129.65M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD 700.4M 376.22M Jun/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.27B 771M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026